As reported in Table 1, anti-VEGF drugs have been related to variable response depending on CXCL8, VEGFA, NRP1, ARMS2, CFH, and HTRA1 genotypes in macular degeneration and depending on VEGFA genotype in CNV patients, without differentiating results among PCV patients. This evidence concerns the gene VEGFA and macular degeneration.